Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

2(40.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06182865Not ApplicableUnknown

A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

Role: lead

NCT05007548Phase 2Completed

to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve

Role: lead

NCT02271516Phase 1Terminated

to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage

Role: lead

NCT03908957Phase 1Completed

to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

Role: lead

NCT02473783Phase 2Completed

The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD

Role: collaborator

All 5 trials loaded